Why 'Results Not Typical' Stopped Protecting Ads

what does ftc example 41 actually describe?

FTC Example 41 describes a before-and-after testimonial that claims a woman lost 16 pounds in eight weeks, while the advertiser’s randomized controlled trial showed an average result of only four pounds over placebo. The issue is not that the testimonial is necessarily fabricated. The issue is that the ad lets one dramatic outcome stand in for the expected consumer experience.

We checked this against the FTC Health Products Compliance Guidance, which treats the 16-pound testimonial as misleading unless the ad gives the real study average prominently and next to the claim. That matters for operators because many supplement funnels still treat a testimonial as a softer claim than body copy. It isn't softer once the advertiser chooses, edits, captions and places it in the sales path.

The useful distinction is simple: a real customer can still create a deceptive ad. If your creative shows the outlier and hides the average, the problem is the impression the ad creates, not whether the endorser exists.

why is a fine-print typicality asterisk considered inadequate?

A fine-print typicality asterisk is inadequate because it asks the reader to downgrade the headline after the damage has already been done. In Example 41, the testimonial tells the saleable story, the image makes it memorable, and the asterisk arrives too late and too quietly to correct the takeaway.

The FTC’s endorsement guidance is blunt on this point: "attempts to disclaim dramatic results with statements like 'Results not typical' don't cure the deception." That line is load-bearing because it turns the old direct-response habit into a compliance liability. The disclaimer is not a magic phrase; it has to change what the reasonable reader understands before they act.

This is where testimonial disclaimer supplement ads are usually misread. The required disclosure is not a decorative legal line under the fold. It is part of the claim architecture, and if the disclosure would be missed by a hurried buyer, it doesn't do the job the ad needs it to do.

• An asterisk near the testimonial is weaker than the actual expected result near the testimonial.
• A footer disclosure is weaker than a same-screen disclosure.
• A vague phrase like "your results may vary" is weaker than the numeric average the study actually found.

what disclosure does the ftc prescribe in its place?

The FTC prescribes a prominent, adjacent statement of the real study average, not a generalized warning that results vary. For the Example 41 fact pattern, that means the ad should tell readers the study showed an average of four pounds over placebo while showing the 16-pound testimonial.

We changed our mind about this after counting the interaction between Example 41 and Gut Check. The fix is not merely more visible legal copy; it is numeric context. If your ad claims a result that sits well above the study average, the disclosure has to give the average in terms the buyer can compare without doing math.

That is why swipe-file research has to track disclosures, not just hooks and formats. A swipe file Facebook ads review that saves the winning testimonial but ignores the study-average disclosure is missing the part that determines whether the claim can survive review.

• Use the actual average from the substantiation file.
• Place it next to the testimonial or result claim.
• Make it prominent enough to be read with the claim, not after the claim.

at what result size does a typicality disclosure become mandatory?

A typicality disclosure becomes mandatory in the weight-loss lane when the endorsement claims an average loss of two pounds or more per week for a month, or more than 15 pounds overall. That trigger comes from the FTC’s Gut Check guidance, not from platform folklore or affiliate-network preference.

The FTC Gut Check reference guide also defines substantial weight loss as "weight loss of a pound a week for more than four weeks or a total weight loss of more than 15 pounds in any time period." That means dress-size claims, inches-off claims and body-fat claims can still trigger the same issue if they communicate the same result.

We could not verify current hard demographics for the weight-loss buyer from CDC/NCHS or NIH ODS in the supplied record; a primary source from those agencies would settle age bands, prior-attempt rates and population figures. That gap does not affect the disclosure trigger, which is stated by FTC in pounds and time.

how prominent and how close to the claim does it have to be?

The disclosure has to be prominent enough and close enough that the reader processes it with the testimonial, not as a later correction. In practice, that means same screen, same visual field and plain numeric wording beside the result claim.

The FTC’s 2022 guidance rejects burying a "no clinical study has been performed" line in Terms and Conditions when lab coats and medical language imply proof, and it treats contradictory disclaimers as ineffective. The same principle applies here: the disclosure must meet the claim where the claim is doing the selling. If your result appears in a video frame, caption, card, advertorial quote block or email subject sequence, the expected-result disclosure needs to be attached to that presentation, not hidden in a legal page.

Creative teams often argue that the disclosure will hurt conversion, and they are probably right. That is not a reason to shrink it; it is evidence the original testimonial was carrying more certainty than the substantiation supports. When we review winning ads creative, the question is not only what made the ad work, but which claim created the performance.

• Close means adjacent to the result claim, not merely somewhere on the page.
• Prominent means readable in the same viewing context as the testimonial.
• Numeric means the real expected result, not only "results vary" or "not typical."

does the dshea disclaimer help here at all?

The DSHEA disclaimer does not solve a misleading testimonial or a weight-loss typicality problem. It is a labeling condition for lawful dietary supplement structure/function claims, not a cure for advertising that implies an unsupported or unrepresentative result.

The required DSHEA wording says, "This product is not intended to diagnose, treat, cure, or prevent any disease." That sentence may be required on supplement labeling, but FTC’s advertising analysis asks what the ad communicates to consumers and whether the advertiser has competent and reliable scientific evidence for that message. A disease disclaimer cannot neutralize a 16-pound visual if the surrounding ad tells readers to expect a similar outcome.

The same principle explains why cloaking and landing-page swaps do not fix claim risk. A cloaking TikTok ads tactic may hide a page from review for a time, but it does not change the claim the buyer sees or the evidence the regulator can quote back.

• DSHEA disclaimer: relevant to supplement labeling structure/function claims.
• Typicality disclosure: relevant to whether a testimonial overstates expected results.
• FTC substantiation: relevant to whether the health or weight-loss claim is supported before the ad runs.

how should testimonials be selected when the study average is modest?

Testimonials should be selected to represent the substantiated outcome, not to dramatize the best case. If the study average is modest, the safest testimonial is boring on purpose: it matches the central tendency, names the time period and avoids implying that the outlier is normal.

We counted the practical claim surfaces in this pattern: testimonial text, before-and-after image, caption, headline, VSL narration, review widget, star rating, influencer read and offer guarantee. Any one of them can move the reader from "this happened once" to "this is what I should expect." That is why the selection process matters before the disclosure process starts. A disclosure can contextualize an outlier, but it cannot make a campaign honest if every visible proof element points away from the real average.

For media buying, this also affects diagnostics. If an ad stops spending, the answer is not always bid, budget or account trust; sometimes the creative asks the platform to approve a claim the destination page cannot substantiate. That is why Facebook ads not spending reviews should include the testimonial and disclosure stack, not just campaign settings.

• Prefer testimonials near the study average when the average is modest.
• Avoid before-and-after images that imply a result the study did not generally produce.
• Do not use "results not typical" as a substitute for the expected-result number.
• Keep affiliate, influencer and marketplace reviews inside the same claim standard as owned copy.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Beside Metformin: Substitute or Augment, Both Lose, The DSHEA Disclaimer Does Not Save a Diabetes Ad, Metabolic Endpoints Do Not Prove Weight Loss, The 'Root Cause' Reframe and Why FDA Still Reaches It, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.